(Q43681569)

25 November 2017

The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom (English)

1 reference

cost-effectiveness analysis

25 November 2017

1 reference

1 reference

5

W John Edmunds

1 reference

25 November 2017

Albert Jan van Hoek

1

1 reference

25 November 2017

Alessia Melegaro

series ordinal

2

1 reference

25 November 2017

Nigel Gay

series ordinal

3

1 reference

25 November 2017

Joke Bilcke

series ordinal

4

1 reference

25 November 2017

language of work or name

English

0 references

publication date

23 November 2011

1 reference

25 November 2017

1 reference

25 November 2017

30

1 reference

25 November 2017

1225-1234

1 reference

25 November 2017

6

1 reference

Theoretical epidemiologic and morbidity effects of routine varicella immunization of preschool children in the United States

25 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.026

Modelling the impact of immunization on the epidemiology of varicella zoster virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.026

Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.026

Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.026

Modeling the effects of varicella vaccination programs on the incidence of chickenpox and shingles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.026

Epidemiology of Varicella-Zoster Virus in England and Wales

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.026

Analysis of varicella vaccine breakthrough rates: implications for the effectiveness of immunisation programmes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.026

One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.026

Primary vaccine failure after 1 dose of varicella vaccine in healthy children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.026

Varicella vaccination in England and Wales: cost-utility analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.026

Economic evaluations of varicella vaccination programmes: a review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.026

Cost-effectiveness of varicella vaccination programs: an update of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.026

Changing varicella epidemiology in active surveillance sites--United States, 1995-2005.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.026

Varicella prevention in the United States: a review of successes and challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.026

Incidence of herpes zoster, 1997-2002.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.026

The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.026

Incidence of Herpes Zoster, Before and After Varicella‐Vaccination–Associated Decreases in the Incidence of Varicella, 1992–2002

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.026

A Population-Based Study of the Incidence and Complication Rates of Herpes Zoster Before Zoster Vaccine Introduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.026

Social contacts and mixing patterns relevant to the spread of infectious diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.026

A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.026

Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.026

Modelling the impact of a combined varicella and zoster vaccination programme on the epidemiology of varicella zoster virus in England.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.026

An analysis of infection control of varicella-zoster virus infections in Addenbrooke's Hospital Cambridge over a 5-year period, 1987-92.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.026

Varicella disease among vaccinated persons: clinical and epidemiological characteristics, 1997-2005.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.026

Ten year follow-up of healthy children who received one or two injections of varicella vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.026

Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.026

The incidence and clinical characteristics of herpes zoster among children and adolescents after implementation of varicella vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.026

Herpes zoster incidence among insured persons in the United States, 1993-2006: evaluation of impact of varicella vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.026

Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.026

10.1016/J.VACCINE.2011.11.026

7 January 2021

Identifiers

DOI

1 reference

25 November 2017

1 reference